| Name | Title | Contact Details |
|---|
Millions of Patients around the world are standing up and taking an active role in their health, including supporting the care innovations that matter most to them. MedStartr enables patients, doctors, institutions, partners, and investors to find and fund the best ideas in healthcare and bring them to life. Join us today!
Visiting Nurse and Hospice for Vermont and New Hampshire (VNH) is a non‐profit organization that has provided home health and hospice care services in Vermont and New Hampshire since 1907. The agency is dedicated to delivering outstanding home- and community-based health and hospice services that enrich the lives of the people they serve. VNH makes home visits to people of all ages and all stages of life – regardless of ability to pay – and also provides communities with education and wellness programs. Currently, VNH serves more than 150 towns in Vermont and New Hampshire and covers 4,000 square miles. VNH caregivers provide services for more than 5,000 people each year and makes more than 150,000 home visits to people of all ages and at all stages of life.
Seton Imaging is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Buffalo, NY. To find more information about Seton Imaging, please visit www.setonimaging.com
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Specialty Media provides innovative products and services of the highest quality to the academic and industrial biological research community. Our products and services are designed with the needs of the bench researcher in mind. Specialty Media offers